Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, Margie Byron, Linna Ding, Sai Kanaparthi, William T Barry, Wendy Gao, Kristin Ryker, Patti Tosta, Anca D Askanase, Susan A Boackle, W Winn Chatham, Diane L Kamen, David R Karp, Kyriakos A Kirou, S Sam Lim, Bradley Marder, Maureen McMahon, Samir V Parikh, William F Pendergraft 3rd, Amber S Podoll, Amit Saxena, David Wofsy, Betty Diamond, Dawn E Smilek, Cynthia Aranow, Maria Dall'Era, Yemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, Margie Byron, Linna Ding, Sai Kanaparthi, William T Barry, Wendy Gao, Kristin Ryker, Patti Tosta, Anca D Askanase, Susan A Boackle, W Winn Chatham, Diane L Kamen, David R Karp, Kyriakos A Kirou, S Sam Lim, Bradley Marder, Maureen McMahon, Samir V Parikh, William F Pendergraft 3rd, Amber S Podoll, Amit Saxena, David Wofsy, Betty Diamond, Dawn E Smilek, Cynthia Aranow, Maria Dall'Era
Abstract
Objective: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN).
Methods: In a multicenter, randomized, open-label clinical trial, 43 patients with recurrent or refractory LN were treated with rituximab, cyclophosphamide (CYC), and glucocorticoids followed by weekly belimumab infusions until week 48 (RCB group), or treated with rituximab and CYC but no belimumab infusions (RC group). Patients were followed up until week 96. Percentages of total and autoreactive B cell subsets in the patients' peripheral blood were analyzed by flow cytometry.
Results: Treatment with belimumab did not increase the incidence of adverse events in patients with refractory LN. At week 48, a complete or partial renal response occurred in 11 (52%) of 21 patients receiving belimumab, compared to 9 (41%) of 22 patients in the RC group who did not receive belimumab (P = 0.452). Lack of improvement in or worsening of LN was the major reason for treatment failure. B cell depletion occurred in both groups, but the percentage of B cells remained lower in those receiving belimumab (geometric mean number of B cells at week 60, 53 cells/μl in the RCB group versus 11 cells/μl in the RC group; P = 0.0012). Percentages of total and autoreactive transitional B cells increased from baseline to week 48 in both groups. However, percentages of total and autoreactive naive B cells decreased from baseline to week 48 in the belimumab group compared to the no belimumab RC group (P = 0.0349), a finding that is consistent with the observed impaired maturation of naive B cells and enhanced censoring of autoreactive B cells.
Conclusion: The addition of belimumab to a treatment regimen with rituximab and CYC was safe in patients with refractory LN. This regimen diminished maturation of transitional to naive B cells during B cell reconstitution, and enhanced the negative selection of autoreactive B cells. Clinical efficacy was not improved with rituximab and CYC in combination with belimumab when compared to a therapeutic strategy of B cell depletion alone in patients with LN.
Trial registration: ClinicalTrials.gov NCT02260934.
© 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Figures
References
- Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:2154–60.
- Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero‐Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016;55:252–62.
- Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies [review]. Curr Opin Rheumatol 2017;29:241–7.
- Feldman CH, Collins J, Zhang Z, Xu C, Subramanian SV, Kawachi I, et al. Azathioprine and mycophenolate mofetil adherence patterns and predictors among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2019;71:1419–24.
- Tektonidou MG, Dasgupta A, Ward MM. Risk of end‐stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta‐analysis. Arthritis Rheumatol 2016;68:1432–41.
- Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222–33.
- Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez‐Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215–26.
- Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead [review]? Nat Rev Rheumatol 2016;12:367–72.
- Kawabata D, Venkatesh J, Ramanujam M, Davidson A, Grimaldi CM, Diamond B. Enhanced selection of high affinity DNA‐reactive B cells following cyclophosphamide treatment in mice. PloS One 2010;5:e8418.
- Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942–5.
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
- Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
- Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG) . Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988;69:927–37.
- Malkiel S, Jeganathan V, Wolfson S, Orduño NM, Marasco E, Aranow C, et al. Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry. Arthritis Rheumatol 2016;68:2210–20.
- Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103–12.
- Diaz‐Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez‐Berriotxoa A, et al. Efficacy of rituximab in 164 patients with biopsy‐proven lupus nephritis: pooled data from European cohorts [review]. Autoimmun Rev 2012;11:357–64.
- Jonsdottir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Long‐term follow‐up in lupus nephritis patients treated with rituximab: clinical and histopathological response. Rheumatology (Oxford) 2013;52:847–55.
- Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886–95.
- The ACCESS Trial Group . Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66:3096–104.
- Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808.
- Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association‐European Dialysis and Transplant Association (EULAR/ERA‐EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82.
- Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the Euro‐Lupus Nephritis regimen in North America. Arthritis Rheumatol 2015;67:1144–6.
- GSK . GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis. December 2019. URL: .
- Regola F, Piantoni S, Lowin T, Archetti S, Reggia R, Kumar R, et al. Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab. Front Pharmacol 2019;10:433.
- Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long‐term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis Rheum 2010;62:201–10.
- Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti–double‐stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672–9.
- Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 2008;111:2744–54.
- Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B‐lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91:586–99.
- Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328–37.
- Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne‐Steele M, et al. Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight 2018;3:e122525.
- Ramskold D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 2019;40:517–27.
- Kraaij T, Kamerling SW, de Rooij EN, van Daele PL, Bredewold OW, Bakker JA, et al. The NET‐effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 2018;91:45–54.
- Anjorin A, Lipsky P. Engaging African ancestry participants in SLE clinical trials. Lupus Sci Med 2018;5:e000297.
Source: PubMed